Apellis Pharmaceuticals Inc to Discuss Phase 3 PEGASUS Study Results - Conference Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : And congrats on the data and the progress. So 2 for me. First, I guess, the answer to this was alluded to in the -- one of the prior question -- answers. But I just wanted to be clear that the 48-week extension data, the long-term PEGASUS data, is not a gating factor to file. So that's just a point of clarification, one. And then secondly, as we think about the potential label expansion opportunities that you're thinking about, whether it's C3G or CAD, maybe you could just give us a sense, given where we are right now and the data that you have in hand and other data that's being read out from potential competitors, how your -- sort of what gating factors are on your mind or how you're weighing the different pros and cons of pursuing some of those other opportunities for pegcetacoplan?

Question: Matthew W. Luchini - BMO Capital Markets Equity Research - Analyst : I just wanted to confirm that the next PEGASUS update, the 48-week is not a gating factor to your ability to file?